MedTrace Logo

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

NCT05181995 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2023-04-07

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)

Conditions

Interventions

DRUG

NYX-783

NYX-783

DRUG

Placebo

Placebo for 50 mg NYX-783

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • Aptinyx

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2023-03-30
Completion
2023-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05181995 on ClinicalTrials.gov